Literature DB >> 19036813

The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Ralph Pantophlet1, Meng Wang, Rowena O Aguilar-Sino, Dennis R Burton.   

Abstract

The human immunodeficiency virus type 1 (HIV-1) envelope spike is a heavily glycosylated trimeric structure in which protein surfaces conserved between different HIV-1 isolates are particularly well hidden from antibody recognition. However, even variable regions on the spike tend to be less antigenic and immunogenic than one might have anticipated for external structures. Here we show that the envelope spike of primary viruses has an ability to restrict antibody recognition of variable regions. We show that access to an artificial epitope, introduced at multiple positions across the spike, is frequently limited, even though the epitope has been inserted at surface-exposed regions on the spike. Based on the data, we posit that restricted antibody access may be the result, at least in part, of a rigidification of the epitope sequence in the context of the spike and/or a highly effective flexible arrangement of the glycan shield on primary viruses. Evolution of the HIV envelope structure to incorporate extra polypeptide sequences into nominally accessible regions with limited antibody recognition may contribute to reducing the magnitude of antibody responses during infection and allow the virus to replicate unhindered by antibody pressure for longer periods.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19036813      PMCID: PMC2643787          DOI: 10.1128/JVI.02046-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  80 in total

Review 1.  Immunologic correlates of protection induced by vaccination.

Authors:  S A Plotkin
Journal:  Pediatr Infect Dis J       Date:  2001-01       Impact factor: 2.129

2.  Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

Authors:  P D Kwong; R Wyatt; S Majeed; J Robinson; R W Sweet; J Sodroski; W A Hendrickson
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

Review 3.  A model for neutralization of viruses based on antibody coating of the virion surface.

Authors:  D R Burton; E O Saphire; P W Parren
Journal:  Curr Top Microbiol Immunol       Date:  2001       Impact factor: 4.291

4.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.

Authors:  M B Zwick; M Wang; P Poignard; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

6.  Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops.

Authors:  P Kolchinsky; E Kiprilov; P Bartley; R Rubinstein; J Sodroski
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region.

Authors:  B Losman; A Bolmstedt; K Schønning; C Westin; E M Fenyö; S Olofsson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-07-20       Impact factor: 2.205

8.  Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

Authors:  R E Means; R C Desrosiers
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more
  16 in total

Review 1.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

2.  Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction.

Authors:  Pierre V Maillard; Vincent Zoete; Olivier Michielin; Didier Trono
Journal:  J Biol Chem       Date:  2010-12-17       Impact factor: 5.157

3.  Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition.

Authors:  Milan Raska; Kazuo Takahashi; Lydie Czernekova; Katerina Zachova; Stacy Hall; Zina Moldoveanu; Matt C Elliott; Landon Wilson; Rhubell Brown; Dagmar Jancova; Stephen Barnes; Jana Vrbkova; Milan Tomana; Phillip D Smith; Jiri Mestecky; Matthew B Renfrow; Jan Novak
Journal:  J Biol Chem       Date:  2010-05-03       Impact factor: 5.157

4.  Introduction of exogenous epitopes in the variable regions of the human immunodeficiency virus type 1 envelope glycoprotein: effect on viral infectivity and the neutralization phenotype.

Authors:  Aaron Wallace; Leonidas Stamatatos
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

Review 5.  Understanding and learning from the success of prophylactic human papillomavirus vaccines.

Authors:  John T Schiller; Douglas R Lowy
Journal:  Nat Rev Microbiol       Date:  2012-09-10       Impact factor: 60.633

Review 6.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

7.  HIV-host interactome revealed directly from infected cells.

Authors:  Yang Luo; Erica Y Jacobs; Todd M Greco; Kevin D Mohammed; Tommy Tong; Sarah Keegan; James M Binley; Ileana M Cristea; David Fenyö; Michael P Rout; Brian T Chait; Mark A Muesing
Journal:  Nat Microbiol       Date:  2016-05-23       Impact factor: 17.745

8.  Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses.

Authors:  M P Cranage; C A Fraser; Z Stevens; J Huting; M Chang; S A Jeffs; M S Seaman; A Cope; T Cole; R J Shattock
Journal:  Mucosal Immunol       Date:  2009-09-09       Impact factor: 7.313

Review 9.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

10.  Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.

Authors:  Laura M Walker; Sanjay K Phogat; Po-Ying Chan-Hui; Denise Wagner; Pham Phung; Julie L Goss; Terri Wrin; Melissa D Simek; Steven Fling; Jennifer L Mitcham; Jennifer K Lehrman; Frances H Priddy; Ole A Olsen; Steven M Frey; Phillip W Hammond; Stephen Kaminsky; Timothy Zamb; Matthew Moyle; Wayne C Koff; Pascal Poignard; Dennis R Burton
Journal:  Science       Date:  2009-09-03       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.